Hepatitis B Core-Related Antigen to Indicate High Viral Load : Systematic Review and Meta-Analysis of 10,397 Individual Participants
Copyright © 2021 AGA Institute. Published by Elsevier Inc. All rights reserved..
BACKGROUND & AIMS: To eliminate hepatitis B virus (HBV) infection, scale-up of testing and treatment in resource-limited countries is crucial. However, access to nucleic acid testing to quantify HBV DNA, an essential test to examine treatment eligibility, remains severely limited. We assessed the performance of a novel immunoassay, HBV core-related antigen (HBcrAg), as a low-cost (less than US $15/assay) alternative to nucleic acid testing to indicate clinically important high viremia in chronic HBV patients infected with different genotypes.
METHODS: We searched Medline, Embase, Scopus, and Web of Science databases through June 27, 2018. Three reviewers independently selected studies measuring HBV DNA and HBcrAg in the same blood samples. We contacted authors to provide individual participant data (IPD). We randomly allocated each IPD to a derivation or validation cohort. We applied optimal HBcrAg cut-off values derived from the derivation set to the validation set to estimate sensitivity/specificity.
RESULTS: Of 74 eligible studies, IPD were obtained successfully for 60 studies (81%). Meta-analysis included 5591 IPD without antiviral therapy and 4806 treated with antivirals. In untreated patients, the pooled area under the receiver operating characteristic curve and optimal cut-off values were as follows: 0.88 (95% CI, 0.83-0.94) and 3.6 log U/mL to diagnose HBV DNA level of 2000 IU/mL or greater; and 0.96 (95% CI, 0.94-0.98) and 5.3 log U/mL for 200,000 IU/mL or greater, respectively. In the validation set, the sensitivity and specificity were 85.2% and 84.7% to diagnose HBV DNA level of 2000 IU/mL or greater, and 91.8% and 90.5% for 200,000 IU/mL or greater, respectively. The performance did not vary by HBV genotypes. In patients treated with anti-HBV therapy the correlation between HBcrAg and HBV DNA was poor.
CONCLUSIONS: HBcrAg might be a useful serologic marker to indicate clinically important high viremia in treatment-naïve, HBV-infected patients.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:19 |
---|---|
Enthalten in: |
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association - 19(2021), 1 vom: 30. Jan., Seite 46-60.e8 |
Sprache: |
Englisch |
---|
Links: |
---|
Themen: |
DNA, Viral |
---|
Anmerkungen: |
Date Completed 18.08.2021 Date Revised 18.08.2021 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1016/j.cgh.2020.04.045 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM309444349 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM309444349 | ||
003 | DE-627 | ||
005 | 20231225133927.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.cgh.2020.04.045 |2 doi | |
028 | 5 | 2 | |a pubmed24n1031.xml |
035 | |a (DE-627)NLM309444349 | ||
035 | |a (NLM)32360825 | ||
035 | |a (PII)S1542-3565(20)30590-5 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Yoshida, Kyoko |e verfasserin |4 aut | |
245 | 1 | 0 | |a Hepatitis B Core-Related Antigen to Indicate High Viral Load |b Systematic Review and Meta-Analysis of 10,397 Individual Participants |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 18.08.2021 | ||
500 | |a Date Revised 18.08.2021 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Copyright © 2021 AGA Institute. Published by Elsevier Inc. All rights reserved. | ||
520 | |a BACKGROUND & AIMS: To eliminate hepatitis B virus (HBV) infection, scale-up of testing and treatment in resource-limited countries is crucial. However, access to nucleic acid testing to quantify HBV DNA, an essential test to examine treatment eligibility, remains severely limited. We assessed the performance of a novel immunoassay, HBV core-related antigen (HBcrAg), as a low-cost (less than US $15/assay) alternative to nucleic acid testing to indicate clinically important high viremia in chronic HBV patients infected with different genotypes | ||
520 | |a METHODS: We searched Medline, Embase, Scopus, and Web of Science databases through June 27, 2018. Three reviewers independently selected studies measuring HBV DNA and HBcrAg in the same blood samples. We contacted authors to provide individual participant data (IPD). We randomly allocated each IPD to a derivation or validation cohort. We applied optimal HBcrAg cut-off values derived from the derivation set to the validation set to estimate sensitivity/specificity | ||
520 | |a RESULTS: Of 74 eligible studies, IPD were obtained successfully for 60 studies (81%). Meta-analysis included 5591 IPD without antiviral therapy and 4806 treated with antivirals. In untreated patients, the pooled area under the receiver operating characteristic curve and optimal cut-off values were as follows: 0.88 (95% CI, 0.83-0.94) and 3.6 log U/mL to diagnose HBV DNA level of 2000 IU/mL or greater; and 0.96 (95% CI, 0.94-0.98) and 5.3 log U/mL for 200,000 IU/mL or greater, respectively. In the validation set, the sensitivity and specificity were 85.2% and 84.7% to diagnose HBV DNA level of 2000 IU/mL or greater, and 91.8% and 90.5% for 200,000 IU/mL or greater, respectively. The performance did not vary by HBV genotypes. In patients treated with anti-HBV therapy the correlation between HBcrAg and HBV DNA was poor | ||
520 | |a CONCLUSIONS: HBcrAg might be a useful serologic marker to indicate clinically important high viremia in treatment-naïve, HBV-infected patients | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Meta-Analysis | |
650 | 4 | |a Systematic Review | |
650 | 4 | |a Diagnosis | |
650 | 4 | |a Hepatitis B Core-Related Antigen | |
650 | 4 | |a Meta-Analysis | |
650 | 4 | |a Sensitivity | |
650 | 4 | |a Specificity | |
650 | 4 | |a Systematic Review | |
650 | 7 | |a DNA, Viral |2 NLM | |
650 | 7 | |a Hepatitis B Core Antigens |2 NLM | |
650 | 7 | |a Hepatitis B Surface Antigens |2 NLM | |
700 | 1 | |a Desbiolles, Alice |e verfasserin |4 aut | |
700 | 1 | |a Feldman, Sarah F |e verfasserin |4 aut | |
700 | 1 | |a Ahn, Sang Hoon |e verfasserin |4 aut | |
700 | 1 | |a Alidjinou, Enagnon K |e verfasserin |4 aut | |
700 | 1 | |a Atsukawa, Masanori |e verfasserin |4 aut | |
700 | 1 | |a Bocket, Laurence |e verfasserin |4 aut | |
700 | 1 | |a Brunetto, Maurizia R |e verfasserin |4 aut | |
700 | 1 | |a Buti, Maria |e verfasserin |4 aut | |
700 | 1 | |a Carey, Ivana |e verfasserin |4 aut | |
700 | 1 | |a Caviglia, Gian Paolo |e verfasserin |4 aut | |
700 | 1 | |a Chen, En-Qiang |e verfasserin |4 aut | |
700 | 1 | |a Cornberg, Markus |e verfasserin |4 aut | |
700 | 1 | |a Enomoto, Masaru |e verfasserin |4 aut | |
700 | 1 | |a Honda, Masao |e verfasserin |4 aut | |
700 | 1 | |a Zu Siederdissen, Christoph Höner |e verfasserin |4 aut | |
700 | 1 | |a Ishigami, Masatoshi |e verfasserin |4 aut | |
700 | 1 | |a Janssen, Harry L A |e verfasserin |4 aut | |
700 | 1 | |a Maasoumy, Benjamin |e verfasserin |4 aut | |
700 | 1 | |a Matsui, Takeshi |e verfasserin |4 aut | |
700 | 1 | |a Matsumoto, Akihiro |e verfasserin |4 aut | |
700 | 1 | |a Nishiguchi, Shuhei |e verfasserin |4 aut | |
700 | 1 | |a Riveiro-Barciela, Mar |e verfasserin |4 aut | |
700 | 1 | |a Takaki, Akinobu |e verfasserin |4 aut | |
700 | 1 | |a Tangkijvanich, Pisit |e verfasserin |4 aut | |
700 | 1 | |a Toyoda, Hidenori |e verfasserin |4 aut | |
700 | 1 | |a van Campenhout, Margo J H |e verfasserin |4 aut | |
700 | 1 | |a Wang, Bo |e verfasserin |4 aut | |
700 | 1 | |a Wei, Lai |e verfasserin |4 aut | |
700 | 1 | |a Yang, Hwai-I |e verfasserin |4 aut | |
700 | 1 | |a Yano, Yoshihiko |e verfasserin |4 aut | |
700 | 1 | |a Yatsuhashi, Hiroshi |e verfasserin |4 aut | |
700 | 1 | |a Yuen, Man-Fung |e verfasserin |4 aut | |
700 | 1 | |a Tanaka, Eiji |e verfasserin |4 aut | |
700 | 1 | |a Lemoine, Maud |e verfasserin |4 aut | |
700 | 1 | |a Tanaka, Yasuhito |e verfasserin |4 aut | |
700 | 1 | |a Shimakawa, Yusuke |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association |d 2003 |g 19(2021), 1 vom: 30. Jan., Seite 46-60.e8 |w (DE-627)NLM147178851 |x 1542-7714 |7 nnns |
773 | 1 | 8 | |g volume:19 |g year:2021 |g number:1 |g day:30 |g month:01 |g pages:46-60.e8 |
856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.cgh.2020.04.045 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 19 |j 2021 |e 1 |b 30 |c 01 |h 46-60.e8 |